SCHEMBL2968428

SCHEMBL2968428

COC(=O)c1cccc(Oc2ccc(Cl)cc2Nc2ccnc3nc(C)ccc23)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.48
L3MBTL1 Q9Y468 5/20 0.44
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 2/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 2/20 0.40
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
MRGPRX4 Q96LA9 2/20 0.39
S1PR4 O95977 1/20 0.39
P2RX3 P56373 3/20 0.39
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
POLB P06746 1/20 0.38
NR4A2 P43354 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2968384 0.92 MRGPRX4 (0.49) IGF1RL3MBTL1MAPK1MRGPRX4P2RX3
SCHEMBL2969761 0.85 IGF1R (0.43) IGF1RMEN1KMT2AALDH1A1MAPT
SCHEMBL2967444 0.85 IGF1R (0.41) IGF1RL3MBTL1MRGPRX4P2RX3POLB
SCHEMBL2960233 0.84 IGF1R (0.43) IGF1RL3MBTL1MEN1KMT2AALDH1A1
SCHEMBL2969143 0.83 L3MBTL1 (0.43) IGF1RL3MBTL1MEN1KMT2AGAA
SCHEMBL2961790 0.83 IGF1R (0.42) IGF1RL3MBTL1MEN1KMT2AALDH1A1
SCHEMBL2968819 0.82 IGF1R (0.45) IGF1RL3MBTL1KMT2AGAAALDH1A1
SCHEMBL2955700 0.81 IGF1R (0.45) IGF1RKMT2AGAAMAPTS1PR4
SCHEMBL2960941 0.81 IGF1R (0.44) IGF1RL3MBTL1KMT2AGAAMAPT
SCHEMBL2960808 0.79 P2RX3 (0.41) IGF1RL3MBTL1GAAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 IGF1R 4518/4885L3MBTL1 2884/4885MEN1 4571/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 IGF1R 4518/4885L3MBTL1 2884/4885MEN1 4571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.